Genentech

FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek

Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication

Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq

Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer

NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling

Analysis of Tumor Mutation, Treatment Data Across Cancers Points to Predictive Biomarkers

NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold

FDA Asks Industry to Come Up With Plans to Address Diversity in Drug, Diagnostic Trials

Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial

Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials

UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC

NICE Recommends Seagen's Tukysa for Advanced HER2-Positive Breast Cancer in England

Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps

FDA Approves Genentech's Rituxan, Chemo for CD20-Positive Pediatric Leukemia, Lymphoma Patients

FDA Approves Genentech's Tecentriq as Adjuvant Treatment for PD-L1-Expressing NSCLC